Expertise: Drug Discovery

 #prevention  #clinicaltrials  #cohorts  #drugdiscovery #riskfactors  #neuroimaging #pharmacology  #exercise  #nutrition  #pollution  #nursing  #psychiatry  #immunology  #lifestyle  #psychology  #cognition #healthyageing #livingwell  #stroke  #mentalhealth  #wayfinding

Sophie profile.jpg
  • Research Gate
  • Twitter

To connect

with Sophie

contact us


#drugdiscovery  #pharmacology 

Sophie is a Senior Lecturer at the University of Glasgow's Institute of Molecular, Cell and Systems Biology and a member of the Scottish Dementia Research Consortium Executive Committee. 


Research within Sophie's laboratory is focussed on defining the therapeutic potential of G protein-coupled receptors (GPCR) in neurodegenerative diseases, such as Alzheimer’s disease.


Specifically, the lab aim to exploit this family of cell-surface receptors to modulate neuroinflammatory processes, and in doing so, offer an approach for modifying progression of disease.

Working with a network of academic and industrial partners  Sophie's group employ an array of experimental approaches which span through novel pharmacology to (chemo)genetic and neurodegenerative disease mouse models.

Dr Sophie Bradley
  • Research Gate

To connect

with Frank

contact us





Professor Frank Gunn-Moore

Frank is the Head of the School of Biology at the University of St Andrews. He is also Deputy Director of the Scottish Universities Life Sciences Alliance and has sat on many different funding agencies.

Frank studied Biological Sciences at the University of Edinburgh, and then a PhD in Biochemistry at the University of Cambridge. After performing postdoctoral research at the Universities of Bristol and Edinburgh, he started my own group in St Andrews, which studies the development and survival of mammalian neurons.


Frank's approach to achieve this has been one of combining all three science disciplines, publishing in biological, chemical and physics-based journals.

His group have made major discoveries in understanding the early stages of Alzheimer’s disease, pioneering new models and identified potential therapeutic targets. In addition, they have developed novel optical technology that allows the manipulation and imaging of cells.